CAS: 846589-98-8; Lorcaserin Hydrochloride
该化合物是一种口服的血清素5-HT2A受体激动剂,用于治疗肥胖症和与体重有关的病症,其主要优势在于其选择性行动机制,它会增加讽刺情绪,减少饥饿,从而便利体重下降,而不会产生重大副作用或与其他药物发生相互作用.
- 英文名称Lorcaserin Hydrochloride
- 中文名称氯卡色林盐酸盐
- IUPAC名称(5R)-7-chloro-5-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine;hydrochloride
- 其它别名1H-3-Benzazepine,8-chloro-2,3,4,5-tetrahydro-1-methyl-, hydr°Chloride, (1R)- (9CI); (R)-8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydr°Chloride; (R)-8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine hydr°Chloride; Lorcaserin hydr°Chloride
- CAS编号846589-98-8
- MFCD编号:MFCD09833667
- EINECS号:112-706-7
- FDA UNII编号:0QJF08GDPE
- 分子式:C11H15Cl2N分子量:232.15
- 产品CID: 1836150
- 产品分类有机原料 → 有机杂环化合物 → 苯氮卓类
MSDS等安全信息
- GHS象形图
- GHS符号GHS08 & GHS07;
注释: Health hazard & Exclamation mark - 危险类别致癌性 类别2
急性毒性 类别4(经口) - 警示词Warning(警告)
- 危险描述H351 |怀疑致癌.
H302 |吞咽有害. - 防范说明P210-P240-P241-P242-P243-P260-P264-P270-P271-P280-P301+P310-P321-P330-P303+P361+P353-P304+P340-P307+P311-P312-P361+P364-P370+P378-P403+P233-P403+P235-P405-P501
- 危险品标志Xi
- 安全声明H303May be harmful if swallowed+H313Skin contact may be harmful+H333Inhalation may be harmful to the body
欧盟法规
C&L通报上下游产品
CAS号616201-80-0 8-氯-2,3,4,5-四氢-...合成工艺路线路线简述
- 合成目标产物 Lorcaserin Hydrochloride 主要起始原料 Lorcaserina
- 616202-92-7 + 87-69-4 = 846589-98-8
反应条件:1.1 Reagents: Potassium Carbonate Solvents: Water; Ph 8 - 9,Rt1.2 Reagents: Hydrochloric Acid Solvents: Ethanol,Ethyl Acetate,Water; Ph 2,Rt; 5 H,Rt
标题:Novel Synthesis Of Antiobesity Drug Lorcaserin Hydrochloride
作者:Zhu,Qihua; Wang,Junwei; Bian,Xueguo; Zhang,Lingzhi; Wei,Ping; Et Al
参考文献:Organic Process Research & Development 日期:2015 卷标:19(9) 页码:1263-1267]
2402743-81-9 = 846589-98-8
反应条件:1.1 Reagents: Trifluoroacetic Acid,Triethylsilane Solvents: Dichloromethane; 2 H,Rt1.2 Reagents: Sodium Bicarbonate Solvents: Water; Rt1.3 Reagents: Sodium Hydroxide Solvents: Water; 20 Min,Ph 10,Rt1.4 Reagents: Hydrochloric Acid Solvents: 1,4-Dioxane; 0 °C; 30 Min,Rt
标题:Light-Enabled Enantiodivergent: Stereospecific Reduction Of Activated Alkenes Using A Single Organocatalyst Enantiomer
作者:Hostmann,Theresa; Molloy,John J.; Bussmann,Kathrin; Gilmour,Ryan
参考文献:Organic Letters 日期:2019 卷标:21(24) 页码:10164-10168]
616202-92-7 = 846589-98-8
反应条件:1.1 Reagents: Hydrochloric Acid Solvents: Diethyl Ether,Dichloromethane
标题:Synthesis Of Enantiopure Antiobesity Drug Lorcaserin
作者:Smilovic,Ivana Gazic; Cluzeau,Jerome; Richter,Frank; Nerdinger,Sven; Schreiner,Erwin; Et Al
参考文献:Bioorganic & Medicinal Chemistry 日期:2018 卷标:26(9) 页码:2686-2690
📜绿卡色林-L-酒石酸盐置于potassium Carbonate,盐酸体系中,用 水,乙酸乙酯 作为反应溶剂,以98%的收率获得产物绿卡色林盐酸盐
参考文献:Administration Of Lorcaserin To Indviduals With Renal Impairment
标题:Administration Of Lorcaserin To Indviduals With Renal Impairment
摘要:本公开涉及一种通过确定个体的肾功能充分性水平并向该个体开具或给予(R)-8-氯-1-甲基-2,3,4,5-四氢-1H-3-苯并噁唑啉或其药学上可接受的盐,溶剂或水合物的治疗有效量来进行个体的体重管理的方法,前提是该个体的肾功能充分性水平选自以下组合:无肾功能障碍,轻度肾功能障碍和中度肾功能障碍.此外,本公开涉及一种通过确定个体的肾功能充分性水平并从需要体重管理的众多个体中选择个体进行(R)-8-氯-1-甲基-2,3,4,5-四氢-1H-3-苯并噁唑啉或其药学上可接受的盐,溶剂或水合物治疗的方法,如果该个体的肾功能充分性水平选自以下组合:无肾功能障碍,轻度肾功能障碍和中度肾功能障碍.
海关参考信息
- 2902600000-乙苯
2902700000-异丙基苯
2903919090-氯苯
2903991000-对氯甲苯 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:WO-2014202765-A1
优先权日:2013-06-21
标题 :Preparation of chiral 1-methyl-2,3,4,5-1h-benzodiazepines via asymmetric reduction of alpha-substituted styrenes
发明人：STAVBER GAJ; GAZIC SMILOVIC IVANA; CLUZEAU JEROME; RICHTER FRANK
权利人:LEK PHARMACEUTICALS
摘要:The present invention provides an asymmetric and economic synthesis of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1 H-benzo[d]azepine via novel intermediates applying an asymmetric enzymatic, biomimetic or catalytic reduction. The present invention also provides a novel green asymmetric catalytic reduction adapted for an aqueous medium to be applied in the synthesis of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1 H-benzo[d]azepine or novel intermediates.
专利号:WO-2015170346-A1
优先权日:2014-05-09
标 题 :A process for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-benzo[d]azepine its enantiomers
发明人：MUTHUKRISHNAN MURUGAN; RAMADOSS VELAYUDHAM; NALLA VISWANADH
权利人:COUNCIL SCIENT IND RES
摘要:The present invention discloses a process for synthesis of Lorcaserin and its analogues using epoxide/chiral epoxide.
专利号:WO-2025096684-A1
优先权日:2023-10-30
标题 :Err modulators
发明人：ELGENDY BAHAA; HEGAZY LAMEES; BURRIS THOMAS
权利人:UNIV OF HEALTH SCIENCES AND PHARMACY IN ST LOUIS
摘要:In one aspect, the present disclosure describes compounds which may be used to modulate the activity of an estrogen receptor-related orphan receptor (EER). Also described are pharmaceutical formulations, methods of synthesis and uses thereof.
专利号:WO-2025096683-A1
优先权日:2023-10-30
标 题:Err modulators
发明人：ELGENDY BAHAA; HEGAZY LAMEES SHAMSELDIN; BURRIS THOMAS PATRICK
权利人:UNIV OF HEALTH SCIENCES AND PHARMACY IN ST LOUIS
摘要:In one aspect, the present disclosure describes compounds that may be used to modulate the activity of an estrogen receptor-related orphan receptor (EER). Also described are pharmaceutical formulations, methods of synthesis and uses thereof.
专利号:CN-105431415-A
优先权日:2013-05-20
标 题:New synthesis of 8-chloro-3-benzo[D]azepines via Friedel-Crafts alkylation of alkenes
专利号:CN-110950802-A
优先权日:2019-12-25
标 题:A kind of synthesis technology of slimming drug greencaserin hydrochloride intermediate
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
合成参考文献
参考文献:10.1007/s11883-007-0061-0
摘要:Neff LM, Aronne LJ. Pharmacotherapy for obesity. Curr Atheroscler Rep. 2007 Dec;9(6):454–62. doi: 10.1007/s11883-007-0061-0.
参考文献:10.1007/s40265-020-01373-1
摘要:Chalhoub RM, Kalivas PW. Non-Opioid Treatments for Opioid Use Disorder: Rationales and Data to Date. Drugs. 2020 Aug 10;80(15):1509–24. doi: 10.1007/s40265-020-01373-1.
📝 需求与反馈
尽可能描述清楚需求与问题信息
